Table of Contents
Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 413589, 8 pages
http://dx.doi.org/10.1155/2012/413589
Clinical Study

Neoadjuvant Chemoradiation in Squamous Cell Carcinoma of the Maxillary Sinus: A 26-Year Experience

1Department of Oral and Cranio-Maxillo and Facial Plastic Surgery, University of Cologne, Kerpener Straße 62, 50931 Cologne, Germany
2Center of Integrated Oncology (CIO) Cologne-Bonn, Kerpener Straße 62, 50931 Cologne, Germany
3Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Straße 62, 50931 Cologne, Germany
4Department of Radiotherapy and Radiation Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
5Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Kerpener Straße 62, 50931 Cologne, Germany

Received 15 May 2012; Revised 21 August 2012; Accepted 2 September 2012

Academic Editor: J. B. Vermorken

Copyright © 2012 Matthias Kreppel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. The aim of our study was to evaluate the effects of neoadjuvant platinum-based radiochemotherapy (RCT) in patients with maxillary sinus squamous cell carcinoma and to compare the results with other multimodality treatment concepts for advanced-stage maxillary sinus carcinoma in the literature. Methods. In total, 53 patients with squamous cell carcinoma of the maxillary sinus were reviewed retrospectively. All patients received a neoadjuvant RCT containing either cisplatin or carboplatin followed by radical surgery. Overall survival and locoregional control were plotted by Kaplan-Meier analysis. Prognostic factors were identified through univariate and multivariate analysis. Results. Five-year overall survival for all patients was 35%. Eleven patients achieved a complete response after radiochemotherapy. The complete response rate was significantly higher for patients treated with cisplatin ( ); however the 5-year overall survival rates did not differ significantly ( ) for patients treated with cisplatin (37%) and carboplatin (32%). Orbital invasion ( ) and complete response to radiochemotherapy ( ) had a significant impact on overall survival in univariate analysis. Conclusions. Neoadjuvant radiochemotherapy followed by radical surgery is an effective treatment for patients with advanced maxillary sinus squamous cell carcinoma. In terms of treatment response cisplatin seems to be more effective than carboplatin.